The $425,000 Newcomer: IgA Nephropathy's Sixth Drug Priced Near the Top, and the Proof Isn't What Bought the Premium

On July 7, 2026, the FDA granted accelerated approvalaccelerated approvalA faster FDA pathway that lets a drug reach patients based on an early stand-in measurement, on the condition the company later proves a real patient benefit in a confirmatory trial. to Vera Therapeutics' atacicept, brand name Trutakna, to reduce proteinuriaproteinuriaProtein leaking into the urine, a sign the kidney's filter is damaged; reducing it is the early signal these drugs are approved on. in adults with primary IgA nephropathy who are at risk of their kidneys getting worse. IgA nephropathy, or IgAN, is a chronic disease in which an antibody clogs the kidney's tiny filters and slowly scars them, sometimes ending in dialysis. Proteinuria, protein leaking into the urine, is the early warning sign that those filters are failing. The approval came with a number: a reported $425,000 annual list price.

That made atacicept the sixth disease-modifying drugdisease-modifying drugA drug that acts on the underlying disease process to slow its progression, rather than just easing symptoms. for a disease that had zero of them in 2020. The reflexive headline wrote itself: another eye-watering rare-disease price. But the reflexive headline misses the interesting part. Atacicept did not slot in at the bottom of a crowding market. It slotted in near the top, the second-most-expensive drug in its class, just under a ceiling set by the priciest incumbent, Novartis's Fabhalta at about $550,000. In a six-drug field, that is not what competition textbooks predict.

Start with what each drug charges per year, from the top. Fabhalta (iptacopan), a Novartis pill that blocks part of the immune 'complement' system, lists at about $550,000. Atacicept follows at $425,000. Otsuka's injected antibody sibeprenlimab, brand name Voyxact, is reported at roughly $390,000. Then a gap: the oral steroid Tarpeyo (budesonide) annualizes to about $181,000, Novartis's endothelin blocker Vanrafia (atrasentan) to about $162,500, and Travere's Filspari (sparsentan) to about $118,800.

Now overlay the evidence. Two of these drugs have full, traditional FDA approval, the kind you only get after a confirmatory trial shows the drug actually slows the loss of kidney function, measured by eGFR, a blood-test-based estimate of how well the kidneys filter. Those two are Tarpeyo (full approval December 2023) and Filspari (full approval September 2024). The other four all reached the market on accelerated approval, a faster lane that clears a drug on the proteinuria surrogate first and demands the hard eGFR proof later.

The two drugs with the most-proven kidney benefit are the two cheapest in the class. The ladder is sorted more by arrival date and mechanism novelty than by proof.

This is the finding that should not happen if price tracked proven benefit. Filspari, the cheapest drug in the class at about $118,800, has full approval on the strength of its PROTECT trial, which showed a slower eGFR decline over two years than an older blood-pressure drug. Tarpeyo, the next cheapest on an annualized basis, has full approval from its NefIgArd trial and was the first IgAN drug ever shown to slow kidney-function loss. Both are old news by this market's standards, Tarpeyo's accelerated nod dates to December 2021, Filspari's to February 2023.

The three most expensive drugs, by contrast, are the three newest to launch and the ones reaching for novel mechanisms, complement inhibition, dual BAFF/APRILBAFF/APRILTwo immune-signaling proteins that drive the harmful antibody production behind IgA nephropathy; atacicept blocks both, aiming at the disease's source. blockade, APRIL blockade. Novelty and recency, not the weight of proof, are what the top of the ladder has in common. If you were pricing purely on demonstrated kidney protection, you would expect the fully-approved veterans near the top. They are at the bottom.

Here is the catch that keeps this honest, and it is important enough that we lead with it rather than bury it. The single most expensive drug in the class also has confirmed benefit. In March 2026, the New England Journal of Medicine published the 24-month results of Fabhalta's APPLAUSE-IgAN trial: the drug slowed the annual decline in kidney function by about 49% versus placebo (an eGFR slopeeGFR slopeHow fast the eGFR filtering score falls per year; a flatter (less negative) slope means the kidneys are declining more slowly, which is the benefit these drugs try to deliver. of roughly -3.10 versus -6.12 per year). That is exactly the hard proof the accelerated pathway is meant to demand, and Fabhalta's list price, the highest in the class at around $550,000, did not move when the proof arrived.

The priciest drug also has confirmed benefit, and the cheapest drug also has confirmed benefit. So proof is not what commands the premium, in either direction.

That single data point disciplines the whole story. It rules out a lazy 'you get what you pay for' reading, because Filspari, a fifth of Fabhalta's price, has proof too. And it rules out an equally lazy 'the expensive drugs are all unproven hype' reading, because the most expensive drug is proven. What the ladder actually sorts on is not the quality of evidence but the newness and mechanistic novelty of the molecule. Proof is scattered across the price range, not concentrated at either end.

To judge these prices against something other than each other, we used the Institute for Clinical and Economic Review (ICERICERThe Institute for Clinical and Economic Review, an independent US non-profit that estimates what a drug's price should be given how much health benefit it delivers.), an independent US non-profit that estimates what a drug should cost given the health it delivers. In its final IgAN evidence report, dated March 31, 2026, ICER put atacicept's fair-value price at $60,000 to $80,000 a year and sibeprenlimab's at $61,000 to $81,000. Atacicept's $425,000 launch is therefore about six times the midpoint of what ICER judges it to be worth, roughly one-sixth of its list price would be 'fair.'

There is an honest exception, and it happens to reinforce the article's spine. ICER scored the old steroid budesonide (Tarpeyo/Nefecon) on a per-course basis and put its fair value at $110,900 to $143,000. ICER's own estimated price for it, about $133,741 per course, sits inside that band. Budesonide is essentially priced at value. The 1.4x figure in the chart comes only from annualizing a nine-month course to twelve months; measured the way ICER measures it, the cheapest, most-established drug is the one drug in the class not overshooting its value line. It is the newer biologics, not the whole class, that tower far above it.

Every number above is a list price, the sticker, before the confidential rebates that drugmakers pay insurers and pharmacy-benefit managers to win coverage. Net prices, what anyone actually pays, are almost never disclosed. That matters here because the whole 'the sixth drug refused to undercut' story rests on list prices, and list is not what determines cost.

The one net figure anywhere near this class is an estimate, not a disclosure. In its March 2026 report, ICER modeled a net pricenet priceWhat a drug actually costs after the confidential rebates a manufacturer pays back to insurers and pharmacy-benefit managers. of about $292,500 for sibeprenlimab, roughly 25% below its reported $390,000 list. But two cautions apply. First, that $292,500 is ICER's modeling assumption, not a number Otsuka published; tellingly, ICER used the very same $292,500 as a placeholder for atacicept before it was even approved. Second, sibeprenlimab's $390,000 'list' is itself a reported estimate, Otsuka never formally announced a Wholesale Acquisition Cost. So the honest position is narrow: if real net discounts run 25% or deeper across the class, atacicept's apparent refusal to undercut could partly dissolve on the prices that actually change hands. We cannot see those prices, so we flag the limit rather than paper over it.

The reason a sixth entrant near the top of the price range is surprising is that crowded drug classes usually behave the other way. The canonical example is hepatitis C. Gilead's Sovaldi launched in 2013 at about $84,000 for a course of treatment and drew national outrage. When AbbVie's Mavyret arrived in 2017, a later rival in a filling field, it launched at about $26,400 a course and was explicitly framed as undercutting the incumbents to expand access. The ladder went down.

Indexing each class to its own first moverfirst moverThe earliest drug to reach a market; in competitive theory later rivals are expected to undercut it, which is what happened in hepatitis C but not here. strips out the fact that hep C is priced per course and IgAN per year, and shows the direction cleanly. Hepatitis C's later rival came in at 31 on a first-mover scale of 100. IgAN's sixth drug came in at 235. Same competitive setup, opposite outcome. The difference is that hepatitis C drugs cured a large population and competed head-to-head on near-identical outcomes, so price was the lever. IgAN's newer entrants each carry a distinct mechanism and a rare-disease label, and none has yet had to compete on a settled, apples-to-apples outcome, so the lever no one is pulling is price.

On the evidence available on approval day, atacicept's $425,000 bought a confirmed reduction in proteinuria, a 46% drop from baseline at 36 weeks, the surrogate the accelerated pathway accepts, and a promise. The hard proof, the eGFR readout from its ORIGIN 3 confirmatory trial, is expected in the third quarter of 2026. It is not yet in hand. Atacicept is, for now, a drug priced second-from-top on the strength of the same early signal that the field's cheaper, longer-proven drugs cleared years ago.

The clean answer to our question is therefore this: the IgAN price ladder ranks drugs mostly by how new and how novel they are, not by how much proof they carry. The two full-approval veterans are the two cheapest. And the reason we can be confident this is about novelty rather than proof is the drug that breaks the neat pattern, Fabhalta, priciest and proven at once. Proof is real, it is valuable, and it is scattered up and down this ladder. It is just not the thing that set the price.